news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

Text | vb Artery Network

Text | vb Artery Network

On the other side of the ocean, another blockbuster news came from medical revenue cycle management, a branch of medical informationization.

R1 RCM (hereinafter referred to as R1), a veteran company in the US healthcare revenue cycle management industry, announced in early August that it had reached a final agreement with the acquirer to sell the company and privatize it for up to US$8.9 billion.This is also another major event in the industry in a short period of time. Waystar, a unicorn company in the industry, just successfully IPOed in early June and raised nearly $1 billion. It is also considered to be the largest IPO in the digital health field in 2024.。

Why is R1 so popular in the capital market? How much room does medical revenue cycle management (RCM), a field that is rarely paid attention to in China, have? Artery Network has sorted out this information for industry reference.

After being forced to buy twice and delisting and relisting, this company is not short of topics

According to the information released by R1, this acquisition is quite dramatic.

Before the acquisition, R1 had two major shareholders. As of February 23, TCP-ASC (an investment vehicle jointly held by investment institution TowerBrook Capital Partners and medical service institution Ascension) and New Mountain Capital, the two major shareholders, jointly held 62% of the common stock, and their equity was very close.